Ipratropium (Br)

Ipratropium (Br) is a quaternary derivative of atropine and a cholinergic blocking agent. It was the first muscarinic receptor blocking agent to acheive wide therapetic use in a pressurized aerosol. Ipratropium (Br) is prepared by chemical synthesis and the racemate is used clinically. It causes dialatation of bronchiol and is used to treat asthma and obstructive pulmonary disease. Ipratropium (Br) is available for inhalational administration.

Brands
ATEM ATEM IPRATEE OPTRA IPRATEC-S IPRATEC IPNEB
Adult Dose
Dose: 20 to 40 mcg
Single Dose: 30 (30)
Frequency: 8 hourly
Route: Inhalation
Instructions: Frequency may be increased upto 4 times/day if needed.
Neonatal
Dose: 12.5 ug/kg
Single Dose: 12 (12.5)
Frequency: 8 hourly
Route: Inhalation
Instructions: Via nebulizer
Paedriatic
Dose: 125 to 0 ug
Single Dose: 62 (62.5)
Frequency: 6 hourly
Route: To total dose of 1mg for asthma).
Instructions:
Characteristics
. It is of Synthetic origin and belongs to Tropane Alkaloid. It belongs to Cholinergic muscarinic antagonist pharmacological group on the basis of mechanism of action and also classified in Respiratory Inhalant Products and Bronchodilator pharmacological group.The Molecular Weight of Ipratropium (Br) is 430.40.
Contraindications
Ipratropium (Br) is contraindicated in conditions like Glucoma,Prostatic hypertrophy,Hypersensitivity,Urinary retention,Bladder obstruction.
Effects
The severe or irreversible adverse effects of Ipratropium (Br), which give rise to further complications include Tachycardia, Palpitation, Angina, Tremors, Arrythmia, Tachycardia.The signs and symptoms that are produced after the acute overdosage of Ipratropium (Br) include Palpitations, Increased heart rate.The symptomatic adverse reactions produced by Ipratropium (Br) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Constipation, Dry mouth, Blurred vision, Rashes, Urticaria, Dyspepsia, Nausea and vomiting, Nasal congestion, Backache, Nasal irritation, Urinary RetentionX, Urinary retention, Dry mouth, dizziness, dyspepsia, Anaphylaxia.
Indications
Ipratropium (Br) is primarily indicated in conditions like Asthma, Bronchospasm prophylaxis, Chronic obstructive pulmonary disease, Reversible airways obstruction, Rhinorrhea, and can also be given in adjunctive therapy as an alternative drug of choice in Rapid reversion to sinus ryhthm.
Interactions
No data regarding the interactions of Ipratropium (Br) was found.
Interfrence
Risks
Drug should not be given to Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inhaler Store Below 40°C. Do not Freeze. Protect from Sunlight and Heat.
Warnings
Ipratropium should be used with caution in patients with medical history especially of glaucoma, prostate trouble or any allergy especially to atropine or other belladonna derivatives. It should be used with caution during pregnancy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.